^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Ambrx Presents Phase 1 Trial Data Update and Phase 2/3 Clinical Trial in Progress for Lead Program ARX788 at the 2020 San Antonio Breast Cancer Symposium

Published date:
12/10/2020
Excerpt:
ORR of 67% (2/3) and DCR of 100% in the 1.5 mg/kg cohort of Phase 1 HER2-positive pan tumor trial in U.S. and Australia...which enrolled patients with HER2 expressing cancers including breast cancer, gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, bladder, colorectal, biliary track, and salivary gland cancers in US and Australia.
Evidence Level:
Sensitive: D – Preclinical
Title:

Nonclinical Development of Next Generation Site-Specific HER2 Targeting Antibody Drug Conjugate (ARX788) for Breast Cancer Treatment

Published date:
06/04/2020
Excerpt:
ARX788 exhibits significant, dose-dependent anti-tumor activity against HER2 expressing breast and gastric xenograft tumors.
DOI:
10.1158/1535-7163.MCT-19-0692